These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 15367880)
1. Monomorphic ventricular tachycardia: a late complication of percutaneous alcohol septal ablation for hypertrophic cardiomyopathy. McGregor JB; Rahman A; Rosanio S; Ware D; Birnbaum Y; Saeed M Am J Med Sci; 2004 Sep; 328(3):185-8. PubMed ID: 15367880 [TBL] [Abstract][Full Text] [Related]
2. Occurrence of de novo sustained monomorphic ventricular tachycardia induced after percutaneous transluminal alcohol septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Hori Y; Ueda M; Nakayama T; Saegusa N; Uehara M; Lee K; Sekine T; Daimon M; Kobayashi Y; Funabashi N; Komuro I Int J Cardiol; 2007 Jul; 119(3):403-7. PubMed ID: 17069908 [TBL] [Abstract][Full Text] [Related]
4. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy. Rigopoulos AG; Daci S; Pfeiffer B; Papadopoulou K; Neugebauer A; Seggewiss H Clin Res Cardiol; 2016 Nov; 105(11):953-961. PubMed ID: 27270758 [TBL] [Abstract][Full Text] [Related]
5. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333 [TBL] [Abstract][Full Text] [Related]
6. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. Alam M; Dokainish H; Lakkis N J Interv Cardiol; 2006 Aug; 19(4):319-27. PubMed ID: 16881978 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety beyond 10 years of percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. de la Torre Hernandez JM; Masotti Centol M; Lerena Saenz P; Sánchez Recalde Á; Gimeno de Carlos F; Piñón Esteban P; Fernandez Rodriguez D; Sitges Carreño M; Sabate Tenas M; Zueco Gil J Rev Esp Cardiol (Engl Ed); 2014 May; 67(5):353-8. PubMed ID: 24774727 [TBL] [Abstract][Full Text] [Related]
12. Radiofrequency catheter ablation for ventricular tachycardia in ischaemic cardiomyopathy due to Kawasaki disease. Komaki H; Nakashima T; Minatoguchi S Cardiol Young; 2018 Jun; 28(6):890-893. PubMed ID: 29656721 [TBL] [Abstract][Full Text] [Related]
13. Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy. Monakier D; Woo A; Puri T; Schwartz L; Ross J; Jamorski M; Yang H; Liu Z; Vannan M; Wigle ED; Rakowski H Am J Cardiol; 2004 Dec; 94(12):1515-22. PubMed ID: 15589007 [TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of combined epicardial and endocardial ablation of monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. Dukkipati SR; d'Avila A; Soejima K; Bala R; Inada K; Singh S; Stevenson WG; Marchlinski FE; Reddy VY Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):185-94. PubMed ID: 21270104 [TBL] [Abstract][Full Text] [Related]
15. Septal alcoholization in hypertrophic cardiomyopathy: about 11 cases. Kambiré Y; Millogo GRC; Dauphin C; Lusson JR Pan Afr Med J; 2017; 27():196. PubMed ID: 28904721 [TBL] [Abstract][Full Text] [Related]